Clal Insurance’s Keros Therapeutics KROS Stock Holding History

Clal Insurance’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-299,000	Closed	-$12M	–	149
2023 Q2	$12M	Hold	299,000	–	–	0.14%	80
2023 Q1	$12.8M	Hold	299,000	–	–	0.19%	71
2022 Q4	$14.4M	Hold	299,000	–	–	0.22%	79
2022 Q3	$11.2M	Hold	299,000	–	–	0.15%	86
2022 Q2	$8.26M	Sell	299,000 -21,000	-7%	-$921K	0.11%	97
2022 Q1	$17.4M	Hold	320,000	–	–	0.18%	86
2021 Q4	$18.7M	Buy	320,000 +8,865	+3%	+$442K	0.2%	88
2021 Q3	$12.3M	Sell	311,135 -8,865	-3%	-$315K	0.14%	108
2021 Q2	$13.6M	Hold	320,000	–	–	0.16%	103
2021 Q1	$19.7M	Hold	320,000	–	–	0.23%	97
2020 Q4	$21.1M	Buy	+320,000	New	+$20.2M	0.29%	84

Other funds holding KROS

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return